Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
Heidelberg University
Heidelberg, AlemaniaPublicaciones en colaboración con investigadores/as de Heidelberg University (54)
2024
-
A multidisciplinary team and patient perspective on omission of surgery after neoadjuvant systemic therapy for early breast cancer: A European Society of Surgical Oncology (ESSO) Research Academy survey
European Journal of Surgical Oncology, Vol. 50, Núm. 10
2023
-
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 610-618
-
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
EJHAEM, Vol. 4, Núm. 4, pp. 1117-1131
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Gut, Vol. 71, Núm. 9, pp. 1856-1866
-
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Obesity Facts, Vol. 15, Núm. 3, pp. 321-335
-
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Clinical Nutrition, Vol. 41, Núm. 4, pp. 990-1000
-
IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387
-
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
Breast, Vol. 63, pp. 123-139
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review
Clinical Nutrition, Vol. 39, Núm. 8, pp. 2368-2388
-
Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma
PLoS ONE, Vol. 15, Núm. 9 September
-
Sarcoma treatment in the era of molecular medicine
EMBO Molecular Medicine, Vol. 12, Núm. 11
2018
-
Heterogeneity within the PF-EPN-B ependymoma subgroup
Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237
-
Intraoperative Electron Radiation Therapy Combined with External Beam Radiation Therapy after Gross Total Resection in Extremity Soft Tissue Sarcoma: A European Pooled Analysis
Annals of Surgical Oncology, Vol. 25, Núm. 13, pp. 3833-3842
-
Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy
Breast Cancer Research and Treatment, Vol. 172, Núm. 3, pp. 523-537
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
An objective comparison of cell-tracking algorithms
Nature Methods, Vol. 14, Núm. 12, pp. 1141-1152